Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART Total Liabilities
Everything the company owes to creditors and other parties.
Integra LifeSciences Holdings CorporationNASDAQ: IART
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $2.54B at the end of Q1 FY2026, up 0.3% from a year earlier and down 0.9% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.
Context
- Total liabilities amounted to 70.9% of total assets at the end of Q1 FY2026, up 8.5 pp from a year earlier.
- Total liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +0.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.56B USD
- Year-over-year change
- +2.7%
- 4-year CAGR
- +5.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.56B | +2.7% |
| FY2024 | 2024-12-31 | 2.49B | +13.6% |
| FY2023 | 2023-12-31 | 2.19B | +5.2% |
| FY2022 | 2022-12-31 | 2.09B | -0.6% |
| FY2021 | 2021-12-31 | 2.1B | — |
Total Liabilities vs competitors
How IART compares with its peers on the latest reported figures
- IART's Mar 2026 total liabilities of $2.54B is the 3rd highest of the 11 companies compared; the peer median is $585.54M.
- Its year-over-year change of +0.3% is the 5th highest of 11, against a peer median of -3.2%.
- Total liabilities amounts to 70.9% of total assets for IART, versus a peer median of 49.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $23.94B | -4.8% | +7.8% | 50.0% | |
| Dec 2025 | $5.17B | +1.6% | +3.2% | 49.4% | |
| Mar 2026 | $2.54B | +0.3% | +7.1% | 70.9% | |
| Mar 2026 | $1.3B | -1.7% | -5.9% | 56.0% | |
| Mar 2026 | $781.22M | -7.9% | +10.8% | 97.7% | |
| Jun 2026 | $719.66M | +8.2% | +47.0% | 13.1% | |
| Mar 2026 | $451.42M | +23.7% | +48.7% | 50.9% | |
| Mar 2026 | $432.69M | -12.9% | -3.0% | 49.0% | |
| Jun 2026 | $75.6M | +29.6% | +11.9% | 126.6% | |
| Sep 2026 | $54.24M | -43.3% | -0.5% | 9.9% | |
| Mar 2026 | $29.4M | -43.4% | +18.3% | 37.7% | |
| Peer median (excluding IART) | $585.54M | -3.2% | +9.3% | 49.7% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 513.45M | 456.66M | 276.4M | 246.38M | 235.05M |
| Short-term Investments | 0 | 0 | 32.69M | 27.19M | 28.69M |
| Net Receivables | 243.24M | 263.47M | 259.33M | 272.37M | 278.85M |
| Inventory | 317.39M | 324.58M | 389.61M | 429.09M | 492.74M |
| Other Current Assets | 13.82M | 31.03M | 32.64M | 29.65M | 28.13M |
| Total Current Assets | 1.15B | 1.16B | 1.06B | 1.08B | 1.16B |
| Property, Plant & Equipment (Net) | 396.25M | 459.59M | 496.38M | 549.77M | 584.9M |
| Goodwill | 1.01B | 1.04B | 1.06B | 1.1B | 615.16M |
| Intangible Assets | 1.15B | 1.13B | 1.07B | 1.21B | 1.13B |
| Long-term Investments | 6.48M | 567.34M | 30.71M | 38.3M | 12.78M |
| Tax Assets | 56.95M | 45.99M | 46.08M | 34.92M | 69.85M |
| Other Non-current Assets | 9.96M | (510.15M) | 27.48M | 28.21M | 25.1M |
| Total Non-current Assets | 2.63B | 2.73B | 2.72B | 2.96B | 2.44B |
| Total Assets | 3.78B | 3.89B | 3.78B | 4.04B | 3.6B |
| Account Payables | 61.84M | 102.1M | 92.33M | 82.5M | 95.73M |
| Short-term Debt | 59.78M | 52.75M | 14.53M | 607.08M | 126.55M |
| Tax Payables | 0 | 0 | 0 | 0 | 3.65M |
| Deferred Revenue | 5.3M | 7.25M | 8.54M | 10.48M | 11.46M |
| Other Current Liabilities | 105.68M | 65.41M | 100.84M | 37.79M | 74.08M |
| Total Current Liabilities | 340.02M | 320.91M | 306.98M | 922.13M | 455.98M |
| Long-term Debt | 1.5B | 1.41B | 1.49B | 1.2B | 1.73B |
| Deferred Tax Liabilities | 45.79M | 63.34M | 35.32M | 60.83M | 5.66M |
| Deferred Revenue (Non-current) | 6.7M | 8.8M | 7.7M | 9.2M | 0 |
| Other Non-current Liabilities | 120.26M | 138.5M | 192.24M | 137.04M | 204.28M |
| Total Non-current Liabilities | 1.76B | 1.76B | 1.89B | 1.57B | 2.1B |
| Total Liabilities | 2.1B | 2.09B | 2.19B | 2.49B | 2.56B |
| Common Stock | 896K | 905K | 909K | 916K | 923K |
| Retained Earnings | 698.57M | 879.12M | 946.86M | 939.92M | 423.44M |
| Accumulated OCI | (45.16M) | 10.27M | (15.11M) | (27.57M) | (30.08M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.68B | 1.8B | 1.59B | 1.55B | 1.04B |
| Total Debt | 1.67B | 1.63B | 1.68B | 1.98B | 2.03B |
| Net Debt | 1.15B | 1.17B | 1.41B | 1.74B | 1.8B |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.